content: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
       Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  
       Date of Report (Date of earliest event reported) January 2, 1997
  
                                       ENZON, INC.
                                       -----------
               (Exact name of registrant as specified in its charter)
  
  
  
    Delaware                       0-12957                               22-237286
    --------                       -------                               ---------
  (State or other jurisdiction    (Commission                       (IRS Employer
  of incorporation)               File Number)                    Identification)
  
  
  
                  20 Kingsbridge Road, Piscataway, New Jersey 08854
                  -------------------------------------------------
                 (Address of principal executive offices) (Zip Code)
  
  
  
          Registrant's telephone number, including area code (908) 980-4500
  
  
  
  
            (Former name or former address, if changed since last report)
  
  
  
  <PAGE>
  
  
  
  Item 5.  Other Events
  -------  ------------
  
       Enzon, Inc. ("Enzon" or the "Company") announced the appointment of Rolf A.
  Classon to the  Company's  Board of  Directors  effective  January 2, 1997.  Mr.
  Classon is currently  president of Bayer  Diagnostics,  part of the Bayer Group,
  and executive vice president of Bayer  Corporation.
  
       Mr.  Classon  joined Bayer in 1991 as senior vice  president of  marketing,
  sales and service.  From  1990-1991,  Mr.  Classon served as president and chief
  operating officer of Pharmacia Biosystems AB. From 1984-1990 he was president of
  Pharmacia  Development  Company,  Inc.  and served as  president of Pharmacia AB
  Hospital Products Division from 1981- 1984. 
  
       Mr. Classon's additional  experience includes serving as a division general
  manager for Swedish  Match Group from  1979-1980,  working as a consultant  from
  1974-1978 for a leading  Scandinavian  consulting firm specializing in strategic
  planning  and   restructuring,   and  serving  as  director  of   organizational
  development of Pharmacia AB from 1969-1974.  
  
       Also, on January 6, 1997,  Enzon was served with a complaint by LBC Capital
  Resources,  Inc.  ("LBC"),  that was filed on December 17,  1996,  in the United
  States  District  Court  for  the  District  of New  Jersey  (Civil  Action  No.
  96-5919(JCL))  asserting that under the May 2, 1995,  letter agreement  ("Letter
  Agreement") between Enzon and LBC, LBC was entitled to a commission comprised of
  $500,000 in cash and warrants to purchase 1,000,000 shares of Enzon common stock
  at an exercise  price of $2.50 per share in connection  with the 1996  financing
  transactions  (collectively,  the  "Financings")  the Company  entered into with
  affiliates  of Genesee  Advisers  ("Genesee").  LBC has also asserted that it is
  entitled to an additional fee
  
                                        - 2 -
  
  <PAGE>
  
  of $175,000 in cash and  warrants to  purchase  250,000  shares of Enzon  common
  stock when and if Genesee exercises any of the warrants obtained pursuant to the
  Financings.  LBC has claimed $3 million in compensatory  damages,  plus punitive
  damages,  counsel fees and costs for the alleged breach of the Letter Agreement.
  The Company  believes that no such commission was due under the Letter Agreement
  and denies any  liability  under the Letter  Agreement.  The Company  intends to
  defend this lawsuit vigorously.
  
  
                                        - 3 -
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
  
  
  
  
  Dated:  January 16, 1997
  
  
  
                                                                       ENZON, INC.
                                                                      (Registrant)
  
                                                       By: /S/ KENNETH J. ZUERBLIS
                                                       ---------------------------
                                                               Kenneth J. Zuerblis
                                                           Vice President, Finance
                                                               and Chief Financial
                                                                          Officer
  
  
                                        - 4 -
metadata_documents: [{"type": "8-K", "sequence": "1", "description": "FORM 8-K", "secsgml_size_bytes": 4634}]
metadata_filer: {"company-data": {"conformed-name": "ENZON INC", "cik": "0000727510", "assigned-sic": "2836", "irs-number": "222372868", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12957", "film-number": "97506812"}, "business-address": {"street1": "20 KINGSBRIDGE RD", "city": "PISCATAWAY", "state": "NJ", "zip": "08854", "phone": "9089804500"}, "mail-address": {"street1": "C/O ROSS & HARDIES", "street2": "65 EAST 55TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10022-3219"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                               Washington, D.C. 20549
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
       Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  
       Date of Report (Date of earliest event reported) January 2, 1997
  
                                       ENZON, INC.
                                       -----------
               (Exact name of registrant as specified in its charter)
  
    Delaware                       0-12957                               22-237286
    --------                       -------                               ---------
  (State or other jurisdiction    (Commission                       (IRS Employer
  of incorporation)               File Number)                    Identification)
  
                  20 Kingsbridge Road, Piscataway, New Jersey 08854
                  -------------------------------------------------
                 (Address of principal executive offices) (Zip Code)
  
          Registrant's telephone number, including area code (908) 980-4500
  
            (Former name or former address, if changed since last report)
  Item 5.  Other Events
  -------  ------------
  
       Enzon, Inc. ("Enzon" or the "Company") announced the appointment of Rolf A.
  Classon to the  Company's  Board of  Directors  effective  January 2, 1997.  Mr.
  Classon is currently  president of Bayer  Diagnostics,  part of the Bayer Group,
  and executive vice president of Bayer  Corporation.
  
       Mr.  Classon  joined Bayer in 1991 as senior vice  president of  marketing,
  sales and service.  From  1990-1991,  Mr.  Classon served as president and chief
  operating officer of Pharmacia Biosystems AB. From 1984-1990 he was president of
  Pharmacia  Development  Company,  Inc.  and served as  president of Pharmacia AB
  Hospital Products Division from 1981- 1984. 
  
       Mr. Classon's additional  experience includes serving as a division general
  manager for Swedish  Match Group from  1979-1980,  working as a consultant  from
  1974-1978 for a leading  Scandinavian  consulting firm specializing in strategic
  planning  and   restructuring,   and  serving  as  director  of   organizational
  development of Pharmacia AB from 1969-1974.  
  
       Also, on January 6, 1997,  Enzon was served with a complaint by LBC Capital
  Resources,  Inc.  ("LBC"),  that was filed on December 17,  1996,  in the United
  States  District  Court  for  the  District  of New  Jersey  (Civil  Action  No.
  96-5919(JCL))  asserting that under the May 2, 1995,  letter agreement  ("Letter
  Agreement") between Enzon and LBC, LBC was entitled to a commission comprised of
  $500,000 in cash and warrants to purchase 1,000,000 shares of Enzon common stock
  at an exercise  price of $2.50 per share in connection  with the 1996  financing
  transactions  (collectively,  the  "Financings")  the Company  entered into with
  affiliates  of Genesee  Advisers  ("Genesee").  LBC has also asserted that it is
  entitled to an additional fee
  
                                        - 2 -
  of $175,000 in cash and  warrants to  purchase  250,000  shares of Enzon  common
  stock when and if Genesee exercises any of the warrants obtained pursuant to the
  Financings.  LBC has claimed $3 million in compensatory  damages,  plus punitive
  damages,  counsel fees and costs for the alleged breach of the Letter Agreement.
  The Company  believes that no such commission was due under the Letter Agreement
  and denies any  liability  under the Letter  Agreement.  The Company  intends to
  defend this lawsuit vigorously.
  
                                        - 3 -
  SIGNATURES
  
           Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
  the  Registrant  has duly  caused  this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  
  Dated:  January 16, 1997
  
                                                                       ENZON, INC.
                                                                      (Registrant)
  
                                                       By: /S/ KENNETH J. ZUERBLIS
                                                       ---------------------------
                                                               Kenneth J. Zuerblis
                                                           Vice President, Finance
                                                               and Chief Financial
                                                                          Officer
  
                                        - 4 -